Abstract
Aim This article determines the optimal time and dose of cadmium chloride (CdCl2) injected to pregnant rat to establish experimental preeclampsia (PE) model. In addition,
the therapeutic potential of BML-111, a lipoxin A4 analogue, in the CdCl2-induced PE model was also evaluated.
Methods Peritoneal injection of two dose of CdCl2 for successive 6 days was tested in the pregnant rats starting from various gestational
days (GDs). During this process, the systolic blood pressure and the body weight of
pregnant rats and neonatal rats were monitored. The pathological changes of the placenta
and kidney were evaluated by hematoxylin and eosin staining. The phosphorylation of
extracellular signal-regulated kinase 1/2 and signal transducer and activator of transcription
3 in the placentas was detected by Western blot, and the messenger ribonucleic acid
expression of interleukin (IL)-6, tumor necrosis factor-α, and IL-10 in the placentas
were detected by real-time polymerase chain reaction. BML-111 at the dose of 1 mg/kg/day
was peritoneally injected into the rat after establishing the PE model to test its
therapeutic potential.
Results In the present study, we successfully established the PE model in pregnant rats by
intraperitoneally injection of CdCl2 at the dose of 0.125 mg/kg/day from GD 9 to 14. We recapitulated multiple features
of clinical PE in CdCl2-induced rat, including high blood pressure, renal dysfunction, and inflammatory response
in placenta. Furthermore, treatment with BML-111 significantly relieved multiple features
in our PE rat model.
Conclusions BML-111 has a potential therapeutic effect in pregnant rats with CdCl2-induced PE, which appears to be mediated through inhibition of inflammatory processes
in the placenta.
Keywords
preeclampsia - BML-111 - cadmium chloride - inflammation
